Browsing: Lilly

The pharmaceutical company Eli Lilly is studying a new obesity drug called retatrutide. The drug has not yet been approved by the Food and Drug Administration, but that hasn’t stopped people from selling unapproved versions

Eli Lilly (NYSE:LLY)HealthcareEli Lilly and Company (NYSE:LLY)1180.16 USD-28.8402.385%Last Updated at: 2026-08-14T20:09:00Z stock drew attention this week as strong demand for the company’s weight-loss and diabetes treatments lifted its guidance, alongside a European regulatory clearance that advanced its lineup, spotlighting the pharmaceutical company’s momentum across the healthcare sector. The company raised its sales guidance after reporting…

Eli Lilly has a broad pipeline of weight-loss products that will help it maintain its lead in this area

This week, the U.K.’s healthcare regulatory body approved Eli Lilly’s (NYSE: LLY) weight loss drug orforglipron, sold as Foundayo, for weight management and type 2 diabetes. Unlike Lilly’s other weight loss drug, Zepbound, Foundayo is a pill, not an injectable medication — and that’s a fresh piece of good news for investors

SAN FRANCISCO, California: Eli Lilly has filed lawsuits against six U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide, stepping up action against unauthorized sellers before the medicine has received regulatory approval

Eli Lilly has initiated a crackdown to curb the trade of illicit forms of its investigational weight loss therapy, retatrutide, as around one in five patients turn to non-vetted sellers to

Eli Lilly’s latest weight loss drug isn’t even on the market yet – but some are selling versions of it. Now, the pharmaceutical giant is suing six companies it says are putting people in danger

Eli Lilly and Co. (LLY, Financials), the pharmaceutical company behind Zepbound and Foundayo, is stepping up its fight against unauthorized sellers of its experimental obesity drug retatrutide

Eli LillyLLY, the drug giant sitting at the center of the obesity boom, filed six lawsuits against businesses it says are illegally selling retatrutide. The timing is striking. Retatrutide is not approved. It is still in Phase 3 trials. Yet Lilly says compounding pharmacies, medical spas and online vendors are already pushing unauthorized versions for…

Eli Lilly is taking six U.S. entities to court for allegedly illegally selling the pharma’s next-generation weight loss candidate retatrutide